American Orthopedic Surgeon and Stem Cell Researcher Presents at World Conference on Regenerative Medicine in Germany

Brian Mehling, M.D., board-certified orthopedic surgeon and CMO of Blue Horizon International, presents data from “Safety Study of Intravenously Administered Human Cord Blood Stem Cells in the Treatment of Symptoms Related to Chronic Inflammation" at international forum
Brian Mehling, M.D.
Brian Mehling, M.D.
NEW YORK - Nov. 6, 2015 - PRLog -- Internationally recognized stem cell researcher and chief medical officer of Blue Horizon International (BHI) and BHI Therapeutic Sciences, Brian Mehling, M.D., and his team presented their research at the World Conference on Regenerative Medicine in Leipzig, Germany.

The World Conference on Regenerative Medicine was held October 21-23, 2015. Researchers, medical practitioners, and company representatives from around the world came together at the Congress Center Leipzig to present and discuss the latest developments and findings in the fields of stem cell research, cell therapy, biomaterials, and tissue engineering.

This was the seventh time the World Conference on Regenerative Medicine was held in Leipzig. The event has evolved into an outstanding platform for international networking and for showcasing joint scientific work in the field of regenerative medicine. The event attracted over  800 attendees, nearly 150 speakers, and more than 280 poster presenters.

“Stem cell therapies are, without a doubt, the future of medicine and we believe their role in treatments will become the preferred substitutes for many surgical, pharmacological, and rehabilitative medical services,” Dr. Mehling stated.  “It is important that doctors and medical professionals are educated on what direction the world will take in regard to stem cell research and therapies. The possibilities are endless. It is crucial for physicians to be aware of the therapies available for patients with different chronic conditions, disorders, and acute diseases.”

BHI Therapuetic Sciences is currently offering cord blood, bone marrow and adipose stem cell derived treatments at Malacky Hospital in Slovakia and is fully licensed by the Ministry of Health of the Slovak Republic.

"We have treated more than 100 patients so far, all with outstanding results. Stem cells are a great option when the patient is not a good candidate for traditional forms of treatment, such as invasive surgery or other treatment modalities," said Mgr Renata Mihalyova, MBA, general manager of Blue Horizon International Slovakia, who attended the conference as well.

Blue Horizon International is a healthcare consulting company with a unique mission that combines treatment, research and philanthropic efforts. Across the globe quality care and services for medical treatments are provided along with resources needed to assist children and adults who are medically underserved. For more information, please visit Blue Horizon International at

Interviews with Dr Mehling  can be arranged through the BHSC media offices at


Like PRLog?
Click to Share